Security Snapshot

BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (BTAI) Institutional Ownership

CUSIP: 09075P105

13F Institutional Holders and Ownership History from Q1 2018 to Q4 2025

Latest Period

Q4 2025

Institutions Reporting

0

Shares (Excl. Options)

0

Price

$0.17

Type / Class
Equity / Common Stock, par value $0.001
Symbol
BTAI on Nasdaq
Shares outstanding
26,011,000
Price per share
$0.17
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
0
Total reported value
$0
Share change
-88
Value change
-$54
Number of holders
0
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Sponsored

Quick Takeaways

  • BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 is tracked under CUSIP 09075P105.
  • 0 institutions reported positions in Q4 2025.
  • 2 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 1 to 0 between Q3 2025 and Q4 2025.
  • Reported value moved from $54 to $0.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Official SEC Source

Backed by Form 13F

Ownership context comes from SEC Form 13F and, when available, Schedule 13D/13G filings.

See Original Filing

Investment Quick Answers

What is CUSIP 09075P105?
CUSIP 09075P105 identifies BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (BTAI) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Oaktree Capital Group Holdings GP, LLC 2.7% -49% $28,939 -$434,154 170,230 -94% Oaktree Capital Holdings, LLC 31 Mar 2025
Qatar Investment Authority 0.6% -92% $26,531 -$436,562 156,066 -94% Qatar Investment Authority 31 Dec 2025

Institutional Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (BTAI) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 0 $0 -$54 $0.17 0
2025 Q3 88 $54 +$54 $0.61 1
2025 Q2 14,875 $5,503 +$5,503 $0.37 1
2025 Q1 0 $0 -$3,224,068 $0.17 0
2024 Q4 8,627,682 $3,224,936 +$2,041,377 $0.37 47
2024 Q3 3,099,756 $1,890,127 -$7,944,274 $0.61 46
2024 Q2 9,738,748 $12,466,903 -$1,711,528 $1.28 71
2024 Q1 9,238,957 $26,053,732 -$415,412 $2.82 71
2023 Q4 9,351,765 $27,595,077 -$1,941,847 $2.95 72
2023 Q3 10,142,059 $25,655,976 -$27,908,890 $2.53 82
2023 Q2 17,642,933 $117,491,802 -$7,226,324 $6.66 83
2023 Q1 17,417,079 $324,965,795 +$71,330,482 $18.66 96
2022 Q4 13,442,183 $288,837,441 +$37,768,271 $21.48 81
2022 Q3 11,865,502 $140,259,937 -$11,714,266 $11.82 82
2022 Q2 12,674,614 $167,321,205 -$8,492,233 $13.20 90
2022 Q1 13,111,117 $273,902,967 -$16,331,751 $20.91 93
2021 Q4 13,927,053 $283,060,517 +$19,228,913 $20.33 90
2021 Q3 12,791,796 $388,253,110 -$6,408,094 $30.35 103
2021 Q2 13,030,148 $378,637,038 +$41,282,735 $29.06 108
2021 Q1 11,015,188 $475,171,234 -$56,530,789 $43.16 114
2020 Q4 12,260,234 $566,451,752 +$16,958,479 $46.20 114
2020 Q3 11,873,463 $514,719,363 +$152,548,583 $43.36 107
2020 Q2 8,121,087 $430,587,215 +$116,997,084 $53.01 103
2020 Q1 5,997,060 $133,825,071 +$39,824,964 $22.35 68
2019 Q4 4,342,692 $63,268,018 +$1,450,806 $14.61 42
2019 Q3 4,179,707 $29,412,098 +$8,120,529 $7.04 41
2019 Q2 2,932,356 $32,048,175 +$4,610,881 $10.96 34
2019 Q1 2,512,687 $24,935,000 +$931,694 $9.89 19
2018 Q4 2,420,717 $9,354,000 -$3,409,943 $3.85 11
2018 Q3 3,251,790 $24,996,000 -$3,807,303 $7.66 17
2018 Q2 3,723,565 $34,207,000 -$9,901,055 $9.20 19
2018 Q1 4,695,186 $47,920,000 +$47,920,000 $10.24 22

Sponsored